Table 1.
Clinical characteristics of MDS patients with diabetes mellitus (DM) or non-DM
| Parameter | All patients n = 890 | DM n = 184 | Non- DM n = 706 | p-value |
|---|---|---|---|---|
| Sex, n (%) | ||||
| Male | 533 (59.9) | 115 (62.5) | 418 (59.2) | 0.416 |
| Female | 357 (40.1) | 69 (37.5) | 288 (40.8) | |
| Median age, year (range) | 60 (18–91) | 63 (23–85) | 59 (18–91) | 0.000 |
| WBC,10^9/L mean (range) | 2.7 (0.3–51.9) | 2.7 (0.6–17.5) | 2.7 (0.3–51.9) | 0.597 |
| ANC, 10^9/L mean (range) | 1.1 (0–28.8) | 1.1 (0–16) | 1.1 (0–28.8) | 0.525 |
| HGB, g/L (range) | 69 (20–171) | 67 (20–152) | 70 (27–171) | 0.238 |
| PLT, 10^9/L mean (range) | 45 (0–988) | 50 (0–805) | 43 (0–988) | 0.265 |
| Serum ferritin, ng/ml mean (range) | 760 (6.9–18,671) | 811 (19.2–8101) | 694 (6.9–18,671) | 0.020 |
| Serum erythropoietin, n (%) | ||||
| < 500 mIU/ml | 314 (35.3) | 77 (41.8) | 237 (33.5) | 0.079 |
| > 500 mIU/ml | 472 (53.0) | 91 (49.5) | 381 (54.0) | |
| Not available | 104 (11.7) | 16 (8.7) | 88 (12.5) | |
| BM blasts percentage, % (range) | 2.7 (0–29) | 2.5 (0–22) | 2.5 (0–29) | 0.553 |
| WHO 2016 subtype, n (%) | ||||
| MDS-SLD | 53 (6.0) | 5 (2.7) | 48 (6.8) | 0.011 |
| MDS-MLD | 379 (42.6) | 84 (45.7) | 295 (41.8) | |
| MDS-RS | 80 (9.0) | 25 (13.6) | 55 (7.8) | |
| MDS-EB-1 | 175 (19.7) | 29 (15.8) | 146 (19.7) | |
| MDS-EB-2 | 170 (19.1) | 38 (20.7) | 132 (19.1) | |
| MDS-5q | 5 (0.6) | 0 (0.0) | 5 (0.7) | |
| MDS-U | 28 (3.5) | 3 (1.6) | 25 (3.5) | |
| IPSS-R risk category, n (%) | ||||
| Very low | 16 (1.8) | 1 (0.5) | 15 (2.1) | 0.298 |
| Low | 178 (20.0) | 43 (23.4) | 135 (19.1) | |
| Intermediate | 328 (36.9) | 64 (34.8) | 264 (37.4) | |
| High | 192 (21.6) | 45 (24.5) | 147 (20.8) | |
| Very high | 114 (12.8) | 20 (10.9) | 94 (13.3) | |
| Not available | 62 (7.0) | 11 (6.0) | 51 (7.2) | |
| Cytogenetic group, n (%) | ||||
| Very good | 9 (1.0) | 4 (2.2) | 5 (0.7) | 0.277 |
| Good | 573 (64.4) | 112 (60.9) | 461 (65.3) | |
| Intermediate | 185 (20.8) | 44 (23.9) | 141 (20.0) | |
| Poor | 43 (4.8) | 10 (5.4) | 33 (4.7) | |
| Very poor | 24 (2.7) | 4 (2.2) | 20 (2.8) | |
| Not available | 56 (6.3) | 10 (5.4) | 46 (6.5) | |
| Incidence of leukemia transformation, n (%) | 123 (13.8) | 27 (14.7) | 96 (13.6) | 0.706 |
| Time of leukemic transformation, month (range) | 15 (0.3–106.8) | 17.8 (0.4–72) | 12.6 (0.3–106.8) | 0.313 |
| Infection, n (%) | ||||
| Yes | 449 (50.4) | 121 (65.7) | 328 (46.5) | 0.000 |
| No | 441 (49.6) | 63 (34.3) | 378 (53.5) | |
| Median overall survival, months | 50.2 | 30.0 | 77.0 | 0.000 |
ANC, absolute neutrophil count; BM bone marrow; DM diabetes mellitus; HGB homoglobin; IPSS-R revised international prognostic scoring system; MDS-SLD MDS with single lineage dysplasia; MDS-MLD MDS with multilineage dysplasia; MDS-RS MDS with ring sideroblasts; MDS-EB-1 MDS with excess blasts-1; MDS-EB-2 MDS with excess blasts-2; MDS-5q, MDS with isolated (5q); MDS-U MDS unclassifiable; PLT platelet; WBC White blood cell count; WHO World Health Organization